Journal articleBr J Cancer2026
Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
- Journal
- Br J Cancer
- Published
- 2 July 2026
- Citations
- 1
- License
- cc by-nc-nd
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract cc by-nc-nd
Background Highly vascularised neuroendocrine tumours (NETs) are attractive targets for foslinanib (CVM-1118), which disrupts vasculogenic mimicry and induces apoptosis via tumour necrosis factor receptor-associated protein 1. We evaluated the efficacy and safety of CVM-1118 in advanced NETs. … Excerpt only: this text is the publisher’s. Read it in full at the source.
Trials 1
- Its registry lists this paper as resultsStudy of CVM-1118 for Patients With Advanced Neuroendocrine Tumors NCT03600233↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.